Search - tctmd.com

Displaying 161 - 180 of 204

Sort: Relevancy | Date

News Daily News

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

May 13, 2013

News Daily News

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

Yael L. Maxwell

May 03, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Presenter: C. Michael Gibson

April 17, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

News Daily News

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

March 28, 2013

Presentation

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

Presenter: Manesh R. Patel

February 03, 2013

News Daily News

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

Caitlin E. Cox

January 30, 2013

News Daily News

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Caitlin E. Cox

January 30, 2013

Presentation AHA 2012

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Presenter: Saurav Chatterjee

November 04, 2012

Presentation TCT 2012

Should Rivaroxaban Be Used in STEMI Patients, and Does Choice of ADP Antagonist (with Rivaroxaban) Matter?

Presenter: C. Michael Gibson

October 25, 2012

Presentation TCT 2012

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Presenter: Harvey White

October 22, 2012

News Daily News

Una Nueva Clase de Anticoagulantes Orales resulta Segura comparada con la Warfarina para Pacientes con FA

October 19, 2012

News Daily News

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

October 19, 2012

News Daily News

El Uso del Dabigatran va a Más tanto contra la FA como Fuera de Indicación

September 12, 2012

News Daily News

Dabigatran Usage up, Both for A-fib and Off-Label Indications

September 12, 2012

News Conference News ESC 2012

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Caitlin E. Cox

September 04, 2012

Presentation ESC 2012

Rivaroxaban in Patients following a ST-Elevation Myocardial Infarction

Presenter: Jessica L. Mega

August 27, 2012

Advertisement

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

ESC Offers Recommendations on Use of New Oral Anticoagulants

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Should Rivaroxaban Be Used in STEMI Patients, and Does Choice of ADP Antagonist (with Rivaroxaban) Matter?

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Una Nueva Clase de Anticoagulantes Orales resulta Segura comparada con la Warfarina para Pacientes con FA

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

El Uso del Dabigatran va a Más tanto contra la FA como Fuera de Indicación

Dabigatran Usage up, Both for A-fib and Off-Label Indications

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Rivaroxaban in Patients following a ST-Elevation Myocardial Infarction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content